Journal article icon

Journal article

Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.

Abstract:

OBJECTIVE: To compare the efficacy of the lipido-sterolic extract of Serenoa repens, Permixon, to that of the alpha-blocker, tamsulosin, in the treatment of severe low urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH). METHODS: In a 12-month, double-blind, randomized study that showed equivalent efficacy of Permixon 320 mg/day and tamsulosin 0.4 mg/day ("PERMAL study"), 685 BPH patients with IPSS > or =10 had been analyzed for efficacy. Of these, the 124 patients with se...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Surgical Sciences, Biomedical Research Centre
Role:
Author
Expand authors...
Journal:
European urology
Volume:
45
Issue:
6
Pages:
773-779
Publication date:
2004-06-05
DOI:
EISSN:
1873-7560
ISSN:
0302-2838
URN:
uuid:d5d5cbf8-e079-465a-82be-af8f3bf62b1a
Source identifiers:
120637
Local pid:
pubs:120637

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP